In brief
- A pilot trial at two hospitals in Ottawa, Canada, has tested daily oral psilocybin microdosing in people with advanced, incurable illnesses and severe psychological distress.
- Table 2 reports global improvement in nine of 13 completers and at least two-point demoralization improvement in eight of 11 assessed, not 72% of all thirteen.
- This is an open-label study without a control group and with a small sample size; the authors proposed a future randomized trial; this review did not verify its launch.
A team from the University of Ottawa has published the results of PSYCHED-PAL, an open trial evaluating daily psilocybin microdosing to alleviate the psychological and existential distress of people with advanced and incurable illnesses. The study, which appeared in the journal Palliative Medicine, points to clinically relevant improvements in depression, anxiety, and demoralization after only three weeks of treatment.
A microdosing protocol, not supervised sessions
Psychological and existential distress—the unease that arises when facing a terminal illness, characterized by fear, loss of meaning, or hopelessness—is common in palliative care and can be difficult to treat; this pilot did not compare every available option. The team led by James Downar enrolled twenty people; characteristics describe the 17 who started, aged 40 to 84 at two Ottawa centers between January 2024 and April 2025; 82% had cancer and an estimated prognosis of one to twelve months. Instead of resorting to a high dose with intensive psychotherapeutic support, the standard model in psilocybin research, the design opted for a protocol of escalating microdoses over three weeks, without formal psychotherapy or supervision of each administration, but with clinical follow-up and vital-sign monitoring. The protocol changed after the first eight enrollments; it is not a self-medication regimen.
What they found
Of 17 starters, 13 completed treatment. Table 2 reports global improvement in nine of 13; at-least-50% reduction in HDRS in five of 13 (38%), HADS depression in eight of 13 (62%) and HADS anxiety in seven of 13 (54%). Demoralization: eight of 11 (72%), with at least a two-point reduction. The abstract differs from the table on several counts; the table is explicitly identified as the source here. Eighteen events occurred (14 mild, four moderate), nine considered possibly or probably related; no serious events were reported. Four withdrew during treatment due to progression or insufficient response.
What it implies
These figures should be read with the caution that the design demands: it is a pilot, open-label study without a placebo group, with a small sample and a considerable dropout rate. Without a comparison group, the effect of expectations or support cannot be ruled out, which is particularly relevant in a context as sensitive as the end of life. The authors themselves acknowledge this and proposed a future randomized controlled trial in the paper; its launch was not verified here. Even so, the work provides a first indication that a microdosing protocol, which is much simpler to administer than high-dose sessions, could have a place in alleviating existential suffering. Evidence on microdosing is, for now, uneven: in other indications, results have been less favorable, as we reported when covering a review on LSD microdosing and ADHD. Those who wish to delve deeper into the state of research can consult our guide on psychedelic science and therapy.
Source
- Downar J, Lapenskie J, Anderson K, Parsons G, Polskaia N, Lalumiere G, Lawlor P. PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. Palliative Medicine, 2026;40(4):514-523, published online January 30, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
